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diarrhoea) from irinotecan-based regimens are not readily available, experts were 
asked to provide frequency estimates and resources associated with management. 
Descriptive statistics were used to summarise the data. RESULTS: The ﬁnal expert 
panel comprised 44 oncologists representing all English NHS regions, from a sample 
of 98 potential experts. Wide variations in prescribing practice were identiﬁed. There 
were ten ﬁrst-line, ten second-line and twelve third-line chemotherapy regimens 
reported, reﬂecting variation in practice. However, dominant treatment pathways 
emerged for each stage of treatment, with: ﬁrst-line treatment with oxaliplatin-based 
regimens, second-line treatment with irinotecan-based regimens, and third-line treat-
ment with mitomycin-based regimens. Experts estimated the frequency of: febrile 
neutropaenia 8.4% (95% CI: 6.7–10.0), septic neutropaenia 4.7% (95% CI: 3.4–6.0), 
and severe diarrhoea 13.1% (95% CI: 10.8–15.5). CONCLUSIONS: This study 
captured the heterogeneity in chemotherapy prescribing practice and patient manage-
ment within CRC specialties and obtained necessary data to inform the appropriate 
model structure for base case and subsequent structural and parameter sensitivity 
analyses.
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OBJECTIVES: Current treatment practices for patients in Australia with advanced 
breast cancer (ABC) who have previously been treated with an anthracycline and a 
taxane (A&T) are not well deﬁned. There is no “gold standard” treatment for these 
heavily pre-treated patients. A retrospective longitudinal survey was conducted to gain 
an insight into the treatments currently used in this patient group. METHODS: Four 
public hospitals provided patient level data. Inclusion criteria encompassed women 
q18 years with ABC who had previously received A&T therapy and had q3 months 
follow-up. Information on demographics, disease characteristics and treatment history 
was obtained from medical records of all eligible patients. Descriptive statistics were 
performed by disease characteristics and treatments prescribed by line of therapy post 
A&T. RESULTS: Data were obtained from 79 patient records. The mean (SD) age at 
initial diagnosis was 51.5 (10.9) years with most patients having stage IIIA disease 
(45.6%). Seventy four patients (93.7%) had previously undergone surgery. The most 
common ﬁrst-line therapies post A&T were monotherapy or combination use of 
radiotherapy (39/79, 49.4%), cytotoxic chemotherapy (36/79, 45.6%), targeted 
therapy (11/79, 13.9%) and hormonal therapy (8/79, 10.3%). Paclitaxel, whether 
used alone or in combination, was the most common ﬁrst-line cytotoxic treatment 
post A&T (11/79, 13.9%), followed by cyclophosphamide (10/79, 12.7%), doxoru-
bicin (9/79, 11.4%) and docetaxel (7/79, 8.9%). Cytotoxic mono-chemotherapies 
were more commonly prescribed ﬁrst-line post A&T than cytotoxic combination 
treatments (31.6% vs. 13.9%) with paclitaxel (9/79, 11.4%), docetaxel (5/79, 6.3%) 
and capecitabine (4/79, 5.1%) being most frequently prescribed. FEC (4/79, 5.1%) 
and doxorubicin/cyclophosphamide (3/79, 3.8%) were the most commonly adminis-
tered cytotoxic ﬁrst-line combinations. CONCLUSIONS: The considerable variation 
in the treatments prescribed for patients with ABC who have previously received A&T 
highlight the need for an effective treatment option. Radiotherapy and cytotoxic che-
motherapy were the most frequently administered therapies, with paclitaxel being 
most commonly prescribed cytotoxic agent.
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OBJECTIVES: Pain, such as pain following Caesarean section is a subjective and 
complex experience, from the intensity of which we can get a forecast with the respect 
of a number of inﬂuencing factors. The aim of this study is to examine those factors 
that inﬂuence postoperative pain after Caesarean section. METHODS: Our examina-
tion was made among women and went through a Caesarean section University of 
Pécs Obstetric and Gynecology Clinic and Hospital of Baranya County between 
October 1, 2008 and December 31, 2008 in Hungary. Our own questionnaire and 
a numerical classiﬁer scale were used to measure the intensity of pain. Under the 
examination time we got back altogether 183 valuable questionnaires from the two 
institutions. Khi2 test, t-test, ANOVA variance analysis, Pearson-Sperman correlation 
coefﬁcient examination was used for the analysis. Data processing was done with SPSS 
15.0 and MS Excel programs. RESULTS: Based on the results of our research a sig-
niﬁcant connection can be shown through the examination of postoperative pain 
following Caesarean section in case of school (p  0.01), the method of anesthesia 
(p  0.002; p  0.041) and the memory of the previous Caesarean section (p  0.03; 
p  0.008). CONCLUSIONS: According to the results of our study those who had 
higher qualiﬁcation had higher postoperative pain intensity and lower functional 
activity than mothers with lower qualiﬁcations. Examining the anesthesia method we 
can say that those mothers who were narcotized reported bigger postoperative pain 
than those mothers who got epidural anesthesia.
PIH2
ADVERSE EVENTS ASSOCIATED WITH THE USE OF SELECTIVE 
SEROTONIN REUPTAKE INHIBITORS (SSRI’S) ANTIDEPRESSANT 
MEDICATIONS AMONG CHILDREN: A REVIEW OF THE FDA ADVERSE 
EVENT REPORTING SYSTEM (AERS)
Chen H
University of Houston, Houston, TX, USA
OBJECTIVES: To examine the adverse events in children treated with SSRIs reported 
through the FDA’s Adverse Event Reporting System in response to the increased risks 
of suicide among children being treated with antidepressants. METHODS: A retro-
spective pharmacovigilance analysis was conducted using the January 2004 to Sep-
tember 2006 FDA Adverse Event Reporting System (AERS) data. The adverse drug 
event cases (ADEs) associated with SSRI antidepressants were identiﬁed based on the 
role of the medication in the incidence of the ADEs as the Primary and Secondary 
suspect. Children were deﬁned as patients below 18 years. RESULTS: Out of 68,936 
ADE cases involving SSRI antidepressants, the SSRIs were identiﬁed as the primary 
suspect in 27,075 cases and as the secondary suspect in 6,713 cases. Of those cases, 
there were merely 1,780 (5.26%) cases involving children. The number of cases 
reported to the FDA per quarter was 161.81 on an average for the 11 quarters data. 
Paroxetine accounted for the majority of the reported ADE, 778 (43.70%) cases 
involving children followed by Sertraline 315 (17.69%) and Escitalopram 273 
(15.33%). Despite the low reporting rate, adverse events associated with SSRI anti-
depressants can have serious consequences. Suicide attempt was reported in 579 cases 
(16.88%) followed by psychotic disorders in 420 cases (12.24%). More than one third 
(608, 38.23%) of those cases led to hospitalization. CONCLUSIONS: Despite that 
the adverse events reported for SSRI antidepressants being taken by children were low; 
the consequences of those adverse events can be very serious. Suicide attempt was the 
most commonly reported adverse event. Paroxetine was the most common SSRI to be 
reported for adverse events and the main outcome was hospitalization.
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OBJECTIVES: Lower urinary tract symptoms (LUTS) secondary to benign prostatic 
hyperplasia (BPH) represent a signiﬁcant burden in affected men, with increasingly 
severe LUTS associated with a lower quality of life (QoL). 2-year primary analyses of 
the CombAT study (n  4844) showed that dutasteride plus tamsulosin provided sig-
niﬁcantly greater symptom and QoL improvement versus either monotherapy. Here 
we present 4-year data on the effects of dutasteride plus tamsulosin compared with 
each monotherapy on the patient-reported health outcomes, BPH Impact Index (BII) 
and International Prostate Symptom Score (IPSS) Q8. METHODS: Following screen-
ing, eligible subjects entered a single-blind run-in period during which they received 
dutasteride and tamsulosin placebos for four weeks. All subjects were then randomised 
to receive 0.5 mg dutasteride, 0.4 mg tamsulosin or the combination once daily for 4 
years. The primary endpoint for the 4-year analysis was time to acute urinary retention 
or BPH-related surgery; secondary endpoints included change from baseline in IPSS, 
BII and IPSS Q8. RESULTS: At baseline, mean BII and IPSS Q8 were 5.3 and 3.6, 
respectively, in all three treatment groups. Mean change from baseline in BII at Month 
48 was 2.2 with combination therapy, 1.8 with dutasteride and 1.2 with tamsu-
losin (both p  0.001 versus combination). For IPSS Q8, the corresponding values 
were 1.5 with combination, 1.3 with dutasteride and 1.1 with tamsulosin (both p 
 0.001 versus combination). Improvement in BII and IPSS Q8 from baseline with 
combination therapy was statistically greater than with dutasteride from 3 months; 
compared with tamsulosin, the improvement from baseline with combination was 
statistically greater from 9 months (BII) and 12 months (IPSS Q8). CONCLUSIONS: 
Dutasteride combined with tamsulosin delivers superior improvement in health out-
comes (BII and IPSS Q8) versus either monotherapy. The superiority of combination 
therapy over dutasteride was observed from three months, and over tamsulosin as 
early as nine months.
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OBJECTIVES: To assess strength and duration of pelvic ﬂoor muscle (PFM) contrac-
tion and to monitor the changes of lifestyle-related factors (body weight, constipation, 
vaginal wall laxity and physical activity) during pregnancy. METHODS: Our study 
focused on examining the strength and duration of pelvic ﬂoor muscle contraction in 
pregnant women during the 2nd and 3rd trimesters. Parameters were measured by a 
device for measuring vaginal pressure. Statistical data were calculated according 
to mean, standard deviation, T-test methods and the results were considered to be 
relevant at p  0.05. RESULTS: Data of 93 women were analyzed. The maximum 
muscle strength of nulliparous women (n  36) was signiﬁcantly higher (p  0.003) 
than that of pregnant women (n  57). The duration of maximum contraction in case 
of nulliparous women proved to be markedly longer (p  0.011) than during preg-
nancy. Regarding lifestyle factors even when BMI and constipation were involved no 
